Compare KOSS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOSS | RFL |
|---|---|---|
| Founded | 1953 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Real Estate |
| Sector | Consumer Staples | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 54.4M |
| IPO Year | N/A | N/A |
| Metric | KOSS | RFL |
|---|---|---|
| Price | $4.81 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.7K | ★ 134.0K |
| Earning Date | 01-29-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,493,080.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.58 | ★ 43.96 |
| 52 Week Low | $4.00 | $1.17 |
| 52 Week High | $8.59 | $3.19 |
| Indicator | KOSS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 73.94 |
| Support Level | $4.56 | $1.21 |
| Resistance Level | $4.86 | $1.57 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 19.66 | 90.00 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.